Health Care • Medical/Dental Instruments
$0.45 ▼ -0.02
(-3.55%)
MKT CAP: $21.0M • VOL: 207.1K
52W L $0 52W H $2
ROARABLE / RQD
D- • 38/100
PIOTROSKI
4 / 9
NSPR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $9.0M | $7.0M | $6.2M |
| YoY Revenue Growth % | +28.1% | +13.0% | — |
| Gross Profit | $2.6M | $1.5M | — |
| Gross Margin % | 29.5% | 21.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$49.6M | -$33.5M | -$21.1M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$48.8M | -$32.0M | -$19.9M |
| EBITDA (Normalized) | -$48.3M | -$32.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$35.1M | -$21.9M | -$16.4M |
| Capital Expenditures (CapEx) | $1.7M | $1.4M | — |
| Free Cash Flow (FCF) | -$36.8M | -$23.3M | -$16.4M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $8.9M | $18.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $55.2M | $36.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NSPR.